MedWatch

US-based obesity firm hires former Novo VP

Ed Cinca, who was behind the launches of Ozempic, Rybelsus and Wegovy at Novo Nordisk, has joined Currax Pharmaceuticals, which also has an obesity drug among its products.

After more than 18 years at Novo Nordisk, Ed Cinca left the Danish pharmaceutical company in July.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs